Focused extracorporeal shockwave therapy (F-ESWT) is a non-invasive treatment modality with the strongest evidence supporting its use in plantar fasciitis, calcific shoulder tendinitis, and knee osteoarthritis, with emerging evidence in erectile dysfunction, low back pain, and cervical spondylosis. Benefits are dose-dependent, with higher-energy protocols generally producing superior outcomes.
Conditions with Strongest Evidence
Plantar fasciitis represents the best-supported indication. A pivotal FDA multicenter RCT (n = 246) demonstrated a 69.2% reduction in heel pain with F-ESWT versus 34.5% with placebo (p = 0.0027), with success rates of 50–65%. High-quality evidence from systematic reviews confirms large effect sizes for both pain and function in chronic plantar fasciitis. Meta-analysis of foot and ankle studies showed a mean VAS difference of −3.10 points favoring ESWT over placebo/conservative treatment.
Calcific shoulder tendinitis is another well-established indication. A systematic review of 20 RCTs found that high-energy ESWT was significantly superior to placebo in decreasing pain, improving function (Constant-Murley score), and achieving complete resorption of calcifications. Piezoelectric focused generators have demonstrated calcification resorption rates of approximately 82.6%. Importantly, ESWT shows no benefit over placebo in non-calcific rotator cuff disease.
Knee osteoarthritis has growing support. Meta-analyses demonstrate significant pain reduction at short, medium, and long-term follow-up compared to sham, with improvements in function at short-term. ESWT was also superior to corticosteroid and hyaluronic acid injections for both pain and function.
Conditions with Emerging
- Lumbar facet joint pain: A sham-controlled RCT (n = 128) showed a 64.4% VAS reduction at 12 months with high-energy F-ESWT, with MRI-confirmed resolution of bone marrow edema in 58.8% of treated patients.
- Cervical spondylosis: A multicenter RCT (n = 320) demonstrated significantly improved VAS, NDI, ROM, and SF-36 scores versus sham, with an overall efficacy rate exceeding 90%.
Mechanism of Action
F-ESWT works through mechanotransduction — converting acoustic energy into biological responses:
- Neovascularization via upregulation of VEGF, eNOS, and PCNA
- Anti-inflammatory effects through NO-mediated suppression of NF-κB
- Tissue regeneration via stem cell recruitment, tenocyte proliferation, and collagen synthesis
- Pain relief through decreased substance P, selective loss of unmyelinated nerve fibers, and serotonergic activation
Benefits are typically gradual rather than immediate, with main follow-up recommended no sooner than 4 months from baseline, as collagen turnover and remodeling require time.
Safety
F-ESWT has an excellent safety profile across all studied indications, with only minor adverse events such as temporary pain, swelling, or bruising reported.